Mode
Text Size
Log in / Sign up
N/A N=31 Randomized Prevention

Metabolic Effects of Sleep Extension in People With Obesity

Insulin Resistance · Obesity

Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Insulin Sensitivity — -3.8; 0.9 µmol/kgFFM/min

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Sleep extension (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
Female
Sponsor
Washington University School of Medicine
Primary completion
Jul 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Insulin Sensitivity
-3.8; 0.9
SECONDARY
Hepatic Insulin Sensitivity Index
0.4; -0.3
SECONDARY
Adipose Tissue Insulin Sensitivity Index
2.4; -2.0
SECONDARY
Homeostatic Model Assessment of Insulin Resistance
0.2; 0.3
SECONDARY
24 Hour Glucose Area Under the Concentration Curve
45; 41
SECONDARY
24 Hour Insulin Area Under the Concentration Curve
1; -44
SECONDARY
24 Hour Non-esterified Fatty Acids Area Under the Concentration Curve
1.0; -0.3
SECONDARY
Body Mass
-1.1; -0.3
SECONDARY
Fat-free Mass
-0.2; -0.5
SECONDARY
Body Fat
0.5; 0.4
SECONDARY
Liver Fat
-0.63; 0.6
SECONDARY
Fasting Glucose
3.6; 0.8
SECONDARY
Daily Time in Bed
0.3; 1.3
SECONDARY
Daily Total Sleep Time
0.0; 1.1
SECONDARY
Stage N1 Sleep Time
-1.3; 6.9
SECONDARY
Stage N2 Sleep Time
-11.7; 23.9
SECONDARY
Stage N3 Sleep Time
4.4; 14.9
SECONDARY
Rapid Eye Movement (REM) Sleep Time
-1.6; 7.6

Summary

This study is designed to determine the impact of extending sleep duration on glucose metabolism in people with obesity. Half of the participants will be instructed to increase their time-in-bed in order to achieve >7h sleep/night (sleep extension; n=15) while the other half will be be instructed to maintain their current sleep habits (n=15).

Eligibility Criteria

Inclusion Criteria

  • Sleep 70 min/wk or moderate exercise >150 min/week
  • Excessive alcohol consumption (>21 units of alcohol per week for men and >14 units of alcohol per week for women)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03594994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search